FDA Approval Insights: Adjuvant Pembrolizumab in Stage IB, II, or IIIA NSCLC

Dr Herbst discusses the FDA approval of adjuvant pembrolizumab in non–small cell lung cancer, key efficacy and safety data from the KEYNOTE-091 trial, and future research efforts that may further improve outcomes in this population.